Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.

Medicina (Kaunas, Lithuania) - 26 May 2022

Kano Yukari, Kataoka Nobutaka, Kunimatsu Yusuke, Tsutsumi Rei, Sato Izumi, Tanimura Mai, Nakano Takayuki, Tanimura Keiko, Takeda Takayuki

Abstract excerpt

Pulmonary pleomorphic carcinoma (PPC) is well-known for its aggressive nature that is usually resistant to platinum-based chemotherapy. On the other hand, the efficacy of an immune checkpoint inhibitor-based regimen in PPC has been elucidated. PPCs harboring epidermal growth factor receptor (EGFR) mutations are extremely rare, and the efficacy of EGFR-tyrosine kinase inhibitors in PPC is limited compared to their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Brain Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Indoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35743969
DOI: 10.3390/medicina58060706
PMCID: PMC9227213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.PMID 35743969Read ↗

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.Semantic proximity Read ↗

Comprehensive molecular profiling of pulmonary pleomorphic carcinomaSemantic proximity Read ↗

Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.Semantic proximity Read ↗

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma.Semantic proximity Read ↗

Pleomorphic Carcinoma With EGFR and Concomitant Mutations Transformed From Lung Adenocarcinoma: A Case Report.Semantic proximity Read ↗

[A case of pulmonary pleomorphic carcinoma with epidermal growth factor receptor (EGFR) mutation].Semantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma.Semantic proximity Read ↗

EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy.Semantic proximity Read ↗

Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy.Semantic proximity Read ↗

[Pulmonary sarcomatoid carcinoma:report of three cases].Semantic proximity Read ↗

The First Case Treated with Larotrectinib of a Novel TMTC2-NTRK3 Fusion Undifferentiated High-Grade Pleomorphic Sarcoma of the ChestSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.